董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Higgins | 男 | Director | 62 | 4.25万美元 | 3.86 | 2025-09-09 |
| Steven Holtzman | 男 | Chair of the Board and Director | 71 | 12.50万美元 | 15.08 | 2025-09-09 |
| Douglas Williams | 男 | Director | 67 | 未披露 | 未持股 | 2025-09-09 |
| Murray Stewart | 男 | Director | 65 | 未披露 | 未持股 | 2025-09-09 |
| Josh Mandel Brehm | 男 | President, Chief Executive Officer and Director | 42 | 69.63万美元 | 57.17 | 2025-09-09 |
| Richard Young | 男 | Director | 71 | 14.25万美元 | 22.06 | 2025-09-09 |
| Murray Stewart | 男 | Director | 64 | 未披露 | 未持股 | 2025-09-09 |
| Amir Nashat | 男 | Director | 52 | 未披露 | 171.60 | 2025-09-09 |
| Andrew J. Schwab | 男 | Director | 54 | 未披露 | 201.88 | 2025-09-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Josh Mandel Brehm | 男 | President, Chief Executive Officer and Director | 42 | 69.63万美元 | 57.17 | 2025-09-09 |
| David Bumcrot | 男 | Chief Scientific Officer and Senior Vice President of Research | 63 | 50.19万美元 | 13.44 | 2025-09-09 |
| Kelly Gold | 女 | Chief Financial Officer | 48 | 62.88万美元 | 13.99 | 2025-09-09 |
| Yuri Maricich | 男 | Chief Medical Officer | 44 | 未披露 | 0.83 | 2025-09-09 |
董事简历
中英对照 | 中文 | 英文- Michael Higgins
-
2015年7月以来Michael Higgins担任Genocea Biosciences董事会的一员。2015年1月作为一名常驻企业家Higgins先生加入了Polaris的合作伙伴。加入Polaris 伙伴之前，Higgins先生担任Ironwood Pharmaceuticals公司的首席运营官和首席财务官。NASDAQ：IRWD从2003年到2014年12月。他在Ironwood工作之前，从1997年到2003年Higgins先生在Genzyme公司担任不同的领导职位包括副总裁、企业融资和副总裁、业务发展。在Genzyme期间，他参与多家企业包括细胞疗法、基因治疗、孤儿疾病业务单位。之前，从1992年到1997年Higgins先生担任Procept公司首席财务官。他也任职于 Genocea Biosciences公司Genocea和 。（纳斯达克：GNCA）和Pulmatrix公司董事会。在1986年作为Schering-Plough 公司的销售代表Higgins先生开始他的制药生涯。Higgins获得Cornell大学理学学士学位和，Dartmouth学院Amos Tuck 商学院的工商管理硕士学位。
Michael Higgins,has served as a member of Board since 2017. Mr. Higgins is a serial entrepreneur who has helped launch and build numerous companies during his career. He served as Interim Chief Executive Officer of Voyager Therapeutics from June 2021 to March 2022. Prior to that time, he was an Entrepreneur-in-Residence at Polaris Partners, a venture capital firm, from 2015 to 2020. From 2003 to 2014 he served as Senior Vice President, Chief Operating Officer at Ironwood Pharmaceuticals Inc, a biopharmaceutical company. Prior to 2003, Mr. Higgins held a variety of senior business positions at Genzyme Corporation, including Vice President of Corporate Finance and Vice President of Business Development. Mr. Higgins has served as a member of the board of directors of Voyager Therapeutics, Inc. ("Voyager") since 2015. He was appointed Chair of the board of directors of Voyager in June 2019. Mr. Higgins has also served as a member of the board of directors of Cyclerion Therapeutics, Inc., a biopharmaceutical company, since November 2023 and as chair of the board of directors of Pulmatrix, Inc., a biopharmaceutical company, since April 2020. Mr. Higgins previously served as a member of the board of directors of Genocea Biosciences Inc., an immuno-oncology company, from 2015 to May 2022. Mr. Higgins earned a BS from Cornell University and an MBA from the Amos Tuck School of Business at Dartmouth College. - 2015年7月以来Michael Higgins担任Genocea Biosciences董事会的一员。2015年1月作为一名常驻企业家Higgins先生加入了Polaris的合作伙伴。加入Polaris 伙伴之前，Higgins先生担任Ironwood Pharmaceuticals公司的首席运营官和首席财务官。NASDAQ：IRWD从2003年到2014年12月。他在Ironwood工作之前，从1997年到2003年Higgins先生在Genzyme公司担任不同的领导职位包括副总裁、企业融资和副总裁、业务发展。在Genzyme期间，他参与多家企业包括细胞疗法、基因治疗、孤儿疾病业务单位。之前，从1992年到1997年Higgins先生担任Procept公司首席财务官。他也任职于 Genocea Biosciences公司Genocea和 。（纳斯达克：GNCA）和Pulmatrix公司董事会。在1986年作为Schering-Plough 公司的销售代表Higgins先生开始他的制药生涯。Higgins获得Cornell大学理学学士学位和，Dartmouth学院Amos Tuck 商学院的工商管理硕士学位。
- Michael Higgins,has served as a member of Board since 2017. Mr. Higgins is a serial entrepreneur who has helped launch and build numerous companies during his career. He served as Interim Chief Executive Officer of Voyager Therapeutics from June 2021 to March 2022. Prior to that time, he was an Entrepreneur-in-Residence at Polaris Partners, a venture capital firm, from 2015 to 2020. From 2003 to 2014 he served as Senior Vice President, Chief Operating Officer at Ironwood Pharmaceuticals Inc, a biopharmaceutical company. Prior to 2003, Mr. Higgins held a variety of senior business positions at Genzyme Corporation, including Vice President of Corporate Finance and Vice President of Business Development. Mr. Higgins has served as a member of the board of directors of Voyager Therapeutics, Inc. ("Voyager") since 2015. He was appointed Chair of the board of directors of Voyager in June 2019. Mr. Higgins has also served as a member of the board of directors of Cyclerion Therapeutics, Inc., a biopharmaceutical company, since November 2023 and as chair of the board of directors of Pulmatrix, Inc., a biopharmaceutical company, since April 2020. Mr. Higgins previously served as a member of the board of directors of Genocea Biosciences Inc., an immuno-oncology company, from 2015 to May 2022. Mr. Higgins earned a BS from Cornell University and an MBA from the Amos Tuck School of Business at Dartmouth College.
- Steven Holtzman
-
Steven Holtzman自2016年4月起担任Visterra, Inc.的董事之一。自2016年7月起，他担任Decibel Therapeutics, Inc.（一家发现和开发治疗听力损失和其他听力障碍的新治疗方法的公司）的总裁兼首席执行官。自2015年以来，他还担任Molecular Partners AG（一家在SIX Swiss Exchange上市的生物制药公司）的董事会成员。从2011年1月到2016年7月，他担任Biogen公司的执行副总裁，负责企业发展，在那里他领导项目领导和管理小组通过六个新药批准，并通过成功完成许多交易领导业务发展和并购小组。加入Biogen之前，他曾担任Infinity Pharmaceuticals, Inc.（癌症药物发现和开发公司）的创始人兼首席执行官。从2001年到2012年，他担任Infinity的董事会主席。2004年至2011年，他担任Anadys Pharmaceuticals, Inc.（一家生物制药公司，随后被F. Hoffman-La Roche Ltd 。的一个部门收购）的董事会成员。在创立Infinity之前，他还担任Millennium Pharmaceuticals, Inc.（现为Takeda Oncology，一家遗传学和基因组学公司）的首席商务官，以及DNX Corporation（一家转基因动物公司）的创始人、董事会成员和执行副总裁。此外，从1996年到2001年，他担任美国国家生物伦理咨询委员会的presidential任命。他获得了密歇根州立大学的学士学位和牛津大学科珀斯克里斯蒂学院的哲学学士学位，并作为Rhodes Scholar参加了该学院。
Steven Holtzman,has served as Chair of Board and as a Strategic Business Advisor to company since October 2019. Mr. Holtzman was the first President and Chief Executive Officer and a member of the board of directors of Decibel Therapeutics, Inc., a biotechnology company, from 2016 to January 2020. Prior to Decibel, Mr. Holtzman served as Executive Vice President, Corporate Development of Biogen, Inc. from 2011 to 2016. Prior to Biogen, Mr. Holtzman served as the Chief Executive Officer of Infinity Pharmaceuticals, Inc. from 2001 to 2010. Mr. Holtzman has also served as a member of the board of directors of Molecular Partners AG, a clinical-stage biopharmaceutical company since May 2014. Mr. Holtzman earned a BA in Philosophy from Michigan State University and a BPhil in Philosophy from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar. - Steven Holtzman自2016年4月起担任Visterra, Inc.的董事之一。自2016年7月起，他担任Decibel Therapeutics, Inc.（一家发现和开发治疗听力损失和其他听力障碍的新治疗方法的公司）的总裁兼首席执行官。自2015年以来，他还担任Molecular Partners AG（一家在SIX Swiss Exchange上市的生物制药公司）的董事会成员。从2011年1月到2016年7月，他担任Biogen公司的执行副总裁，负责企业发展，在那里他领导项目领导和管理小组通过六个新药批准，并通过成功完成许多交易领导业务发展和并购小组。加入Biogen之前，他曾担任Infinity Pharmaceuticals, Inc.（癌症药物发现和开发公司）的创始人兼首席执行官。从2001年到2012年，他担任Infinity的董事会主席。2004年至2011年，他担任Anadys Pharmaceuticals, Inc.（一家生物制药公司，随后被F. Hoffman-La Roche Ltd 。的一个部门收购）的董事会成员。在创立Infinity之前，他还担任Millennium Pharmaceuticals, Inc.（现为Takeda Oncology，一家遗传学和基因组学公司）的首席商务官，以及DNX Corporation（一家转基因动物公司）的创始人、董事会成员和执行副总裁。此外，从1996年到2001年，他担任美国国家生物伦理咨询委员会的presidential任命。他获得了密歇根州立大学的学士学位和牛津大学科珀斯克里斯蒂学院的哲学学士学位，并作为Rhodes Scholar参加了该学院。
- Steven Holtzman,has served as Chair of Board and as a Strategic Business Advisor to company since October 2019. Mr. Holtzman was the first President and Chief Executive Officer and a member of the board of directors of Decibel Therapeutics, Inc., a biotechnology company, from 2016 to January 2020. Prior to Decibel, Mr. Holtzman served as Executive Vice President, Corporate Development of Biogen, Inc. from 2011 to 2016. Prior to Biogen, Mr. Holtzman served as the Chief Executive Officer of Infinity Pharmaceuticals, Inc. from 2001 to 2010. Mr. Holtzman has also served as a member of the board of directors of Molecular Partners AG, a clinical-stage biopharmaceutical company since May 2014. Mr. Holtzman earned a BA in Philosophy from Michigan State University and a BPhil in Philosophy from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar.
- Douglas Williams
-
Douglas Williams，董事长兼董事:DouglasE.Williams博士目前是Codiak BioSciences的总裁、首席执行官和董事会成员。2011年1月至2015年7月，他曾担任Biogen研究与开发的高管Vice President。他从ZymoGenetics公司加入Biogen公司，在那里他最近担任首席执行官兼董事会成员。此前，他曾担任生物技术行业的领导职务，包括西雅图遗传学公司（Seattle Genetics）的首席科学官兼研究与开发执行Vice President，以及安进公司（Amgen）的高级副总裁和华盛顿站点负责人。Williams博士十多年来在Immunex公司担任过一系列科学和高级领导职务，包括执行Vice President和首席技术官以及董事会成员。在他三十多年的生物技术行业职业生涯中，他在包括Enbrel，Tecfidera和Spinraza在内的几种新药的开发中发挥了作用。他曾任职众多生物技术公司的董事会，目前是Ovid Therapeutics公司、AC Immune公司的董事会成员。
Douglas Williams, Chairman and Director: Dr. Douglas E. Williams is currently the President, CEO and member of the Board of Directors of Codiak BioSciences. He was previously Biogen’s Executive Vice President, Research and Development, serving in this role from January 2011 to July 2015. He joined Biogen from ZymoGenetics, where he was most recently CEO and member of the Board of Directors. Previously, he held leadership positions within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics, and Senior Vice President and Washington Site Leader at Amgen. Dr. Williams served in a series of scientific and senior leadership positions over a decade at Immunex, including Executive Vice President and Chief Technology Officer and a member of the Board of Directors. During his more than thirty year career in the biotechnology industry he has played a role in the development of several novel drugs including Enbrel, Tecfidera, and Spinraza. He has served on the board of numerous biotechnology companies and is currently a member of the Board of Directors of Ovid Therapeutics, and AC Immune. - Douglas Williams，董事长兼董事:DouglasE.Williams博士目前是Codiak BioSciences的总裁、首席执行官和董事会成员。2011年1月至2015年7月，他曾担任Biogen研究与开发的高管Vice President。他从ZymoGenetics公司加入Biogen公司，在那里他最近担任首席执行官兼董事会成员。此前，他曾担任生物技术行业的领导职务，包括西雅图遗传学公司（Seattle Genetics）的首席科学官兼研究与开发执行Vice President，以及安进公司（Amgen）的高级副总裁和华盛顿站点负责人。Williams博士十多年来在Immunex公司担任过一系列科学和高级领导职务，包括执行Vice President和首席技术官以及董事会成员。在他三十多年的生物技术行业职业生涯中，他在包括Enbrel，Tecfidera和Spinraza在内的几种新药的开发中发挥了作用。他曾任职众多生物技术公司的董事会，目前是Ovid Therapeutics公司、AC Immune公司的董事会成员。
- Douglas Williams, Chairman and Director: Dr. Douglas E. Williams is currently the President, CEO and member of the Board of Directors of Codiak BioSciences. He was previously Biogen’s Executive Vice President, Research and Development, serving in this role from January 2011 to July 2015. He joined Biogen from ZymoGenetics, where he was most recently CEO and member of the Board of Directors. Previously, he held leadership positions within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics, and Senior Vice President and Washington Site Leader at Amgen. Dr. Williams served in a series of scientific and senior leadership positions over a decade at Immunex, including Executive Vice President and Chief Technology Officer and a member of the Board of Directors. During his more than thirty year career in the biotechnology industry he has played a role in the development of several novel drugs including Enbrel, Tecfidera, and Spinraza. He has served on the board of numerous biotechnology companies and is currently a member of the Board of Directors of Ovid Therapeutics, and AC Immune.
- Murray Stewart
-
Murray Stewart自2017年11月27日起担任我们的执行Vice President，研究与开发主管。加入Novelion之前，Stewart博士于2014年4月至2017年11月担任葛兰素史克（GlaxoSmithKline“；GSK”；）的首席医疗官，负责疫苗，制药和消费者业务部门的全球事务。在此之前，Stewart博士于2000年加入GSK，担任英国临床研究与开发副总监，此后，他在GSK担任的职务越来越重要，包括从2010年1月到2014年3月担任GSK&8217；s心血管和代谢治疗领域主管，从2009年12月到2010年12月担任BioHarm Unit临床主管。在加入制药行业之前，Stewart博士曾担任英国（UK）泰恩河畔纽卡斯尔糖尿病中心的糖尿病顾问和高级讲师，并担任顾问医生/荣誉高级讲师和临床服务主管。Stewart博士担任VIVLI的董事会成员，这是一家正在实施临床研究数据共享平台的非营利组织。Stewart博士在英国南安普顿医学院（Southampton Medical School）完成了医学培训，是皇家内科医学院（Royal College of Physicians）的院士。
Murray Stewart has served as Executive Vice President, Head of Research and Development since November 27 2017. Prior to joining Novelion, from April 2014 to November 2017 Dr. Stewart served as chief medical officer of GlaxoSmithKline "GSK" with global responsibility for the vaccines, pharmaceutical and consumer business units. Prior to that, after joining GSK in 2000 as associate director for clinical research and development in the U.K., Dr. Stewart served in positions of increasing responsibility at GSK, including as GSK's therapy area head for the cardiovascular and metabolic therapy areas from January 2010 to March 2014 and the clinical head of the biopharm unit from December 2009 to December 2010. Prior to joining the pharmaceutical industry, Dr. Stewart worked as a diabetes consultant and senior lecturer and was consultant physician/honorary senior lecturer and head of clinical services at the Diabetes Centre, Newcastle upon Tyne in the United Kingdom (UK). Dr. Stewart serves on the board of directors of Vivli, a non-profit organization that is implementing a clinical research data-sharing platform. Dr. Stewart completed his medical training at Southampton Medical School in the UK and is a Fellow of the Royal College of Physicians. - Murray Stewart自2017年11月27日起担任我们的执行Vice President，研究与开发主管。加入Novelion之前，Stewart博士于2014年4月至2017年11月担任葛兰素史克（GlaxoSmithKline“；GSK”；）的首席医疗官，负责疫苗，制药和消费者业务部门的全球事务。在此之前，Stewart博士于2000年加入GSK，担任英国临床研究与开发副总监，此后，他在GSK担任的职务越来越重要，包括从2010年1月到2014年3月担任GSK&8217；s心血管和代谢治疗领域主管，从2009年12月到2010年12月担任BioHarm Unit临床主管。在加入制药行业之前，Stewart博士曾担任英国（UK）泰恩河畔纽卡斯尔糖尿病中心的糖尿病顾问和高级讲师，并担任顾问医生/荣誉高级讲师和临床服务主管。Stewart博士担任VIVLI的董事会成员，这是一家正在实施临床研究数据共享平台的非营利组织。Stewart博士在英国南安普顿医学院（Southampton Medical School）完成了医学培训，是皇家内科医学院（Royal College of Physicians）的院士。
- Murray Stewart has served as Executive Vice President, Head of Research and Development since November 27 2017. Prior to joining Novelion, from April 2014 to November 2017 Dr. Stewart served as chief medical officer of GlaxoSmithKline "GSK" with global responsibility for the vaccines, pharmaceutical and consumer business units. Prior to that, after joining GSK in 2000 as associate director for clinical research and development in the U.K., Dr. Stewart served in positions of increasing responsibility at GSK, including as GSK's therapy area head for the cardiovascular and metabolic therapy areas from January 2010 to March 2014 and the clinical head of the biopharm unit from December 2009 to December 2010. Prior to joining the pharmaceutical industry, Dr. Stewart worked as a diabetes consultant and senior lecturer and was consultant physician/honorary senior lecturer and head of clinical services at the Diabetes Centre, Newcastle upon Tyne in the United Kingdom (UK). Dr. Stewart serves on the board of directors of Vivli, a non-profit organization that is implementing a clinical research data-sharing platform. Dr. Stewart completed his medical training at Southampton Medical School in the UK and is a Fellow of the Royal College of Physicians.
- Josh Mandel Brehm
-
Josh Mandel Brehm，董事Mandel-Brehm先生自2021年9月起担任本公司董事。Mandel-Brehm先生自2017年5月起担任CAMP4 Therapeutics Corporation总裁兼首席执行官，并担任Polaris Partners的企业家合伙人。在2017年5月之前，Mandel-Brehm先生于2013年5月至2017年5月在渤健公司的业务发展部门任职。自2019年10月以来，他还是Vico Therapeutics B.V.的创始人和董事会成员。Mandel-Brehm先生在圣路易斯华盛顿大学获得生物学学士学位，在密歇根大学获得工商管理硕士学位。我们相信Mandel-Brehm先生在生物技术行业的经验使他有资格担任Promis Neurosciences Inc.的董事会成员。
Josh Mandel Brehm,has served as President and Chief Executive Officer of CAMP4 Therapeutics Corporation since May 2017 and as entrepreneur partner with Polaris Partners. Prior to May 2017, Mr. Mandel-Brehm served in business development for Biogen Corporation from May 2013 to May 2017. He has also been a founder and board member for Vico Therapeutics B.V. since October 2019. Mr. Mandel-Brehm earned a Bachelor of Arts degree in Biology from Washington University in St. Louis and a Master of Business Administration from the University of Michigan. - Josh Mandel Brehm，董事Mandel-Brehm先生自2021年9月起担任本公司董事。Mandel-Brehm先生自2017年5月起担任CAMP4 Therapeutics Corporation总裁兼首席执行官，并担任Polaris Partners的企业家合伙人。在2017年5月之前，Mandel-Brehm先生于2013年5月至2017年5月在渤健公司的业务发展部门任职。自2019年10月以来，他还是Vico Therapeutics B.V.的创始人和董事会成员。Mandel-Brehm先生在圣路易斯华盛顿大学获得生物学学士学位，在密歇根大学获得工商管理硕士学位。我们相信Mandel-Brehm先生在生物技术行业的经验使他有资格担任Promis Neurosciences Inc.的董事会成员。
- Josh Mandel Brehm,has served as President and Chief Executive Officer of CAMP4 Therapeutics Corporation since May 2017 and as entrepreneur partner with Polaris Partners. Prior to May 2017, Mr. Mandel-Brehm served in business development for Biogen Corporation from May 2013 to May 2017. He has also been a founder and board member for Vico Therapeutics B.V. since October 2019. Mr. Mandel-Brehm earned a Bachelor of Arts degree in Biology from Washington University in St. Louis and a Master of Business Administration from the University of Michigan.
- Richard Young
-
Richard Young，自2016年起担任Camp4 Therapeutics Corporation董事会成员。Young博士自1984年起担任麻省理工学院生物学教授和怀特海研究所成员。2012年入选美国国家科学院，2019年入选美国国家医学研究院。杨博士曾担任美国国立卫生研究院和世界卫生组织的顾问。Young博士还自2011年起担任生物技术公司Syros Pharmaceuticals, Inc.的董事会成员，并自2017年起担任生物技术公司Omega Therapeutics, Inc.的董事会成员。Young博士在印第安纳大学获得生物科学学士学位，在耶鲁大学获得分子生物物理和生物化学博士学位。
Richard Young,has served as a member of Board since 2016. Dr. Young has served as a Professor of Biology at the Massachusetts Institute of Technology and a member of the Whitehead Institute since 1984. He was elected into the National Academy of Sciences in 2012 and the National Academy of Medicine in 2019. Dr. Young has served as an advisor to the National Institutes of Health and the World Health Organization. Dr. Young previously served as a member of the board of directors of Syros Pharmaceuticals, Inc., a biotechnology company, from 2011 to November 2024, and as a member of the board of directors of Omega Therapeutics, Inc., a biotechnology company, from 2017 to December 2024. Dr. Young earned a BS in Biological Science from Indiana University and a PhD in Molecular Biophysics and Biochemistry from Yale University. - Richard Young，自2016年起担任Camp4 Therapeutics Corporation董事会成员。Young博士自1984年起担任麻省理工学院生物学教授和怀特海研究所成员。2012年入选美国国家科学院，2019年入选美国国家医学研究院。杨博士曾担任美国国立卫生研究院和世界卫生组织的顾问。Young博士还自2011年起担任生物技术公司Syros Pharmaceuticals, Inc.的董事会成员，并自2017年起担任生物技术公司Omega Therapeutics, Inc.的董事会成员。Young博士在印第安纳大学获得生物科学学士学位，在耶鲁大学获得分子生物物理和生物化学博士学位。
- Richard Young,has served as a member of Board since 2016. Dr. Young has served as a Professor of Biology at the Massachusetts Institute of Technology and a member of the Whitehead Institute since 1984. He was elected into the National Academy of Sciences in 2012 and the National Academy of Medicine in 2019. Dr. Young has served as an advisor to the National Institutes of Health and the World Health Organization. Dr. Young previously served as a member of the board of directors of Syros Pharmaceuticals, Inc., a biotechnology company, from 2011 to November 2024, and as a member of the board of directors of Omega Therapeutics, Inc., a biotechnology company, from 2017 to December 2024. Dr. Young earned a BS in Biological Science from Indiana University and a PhD in Molecular Biophysics and Biochemistry from Yale University.
- Murray Stewart
-
Murray Stewart，自2025年3月起担任董事会成员。Stewart博士于2022年11月至2023年9月期间担任生物制药公司X4 Pharmaceuticals, Inc.的临时首席医疗官。他此前曾于2021年9月至2022年9月担任生物制药公司Rhythm Pharmaceuticals, Inc.的高级医疗顾问，在此之前，于2018年至2021年9月担任首席医疗官。他此前曾于2017年至2018年担任生物制药公司Novelion Therapeutics Inc.的研发主管。在此之前，Stewart博士在葛兰素史克担任过多个职责日益增加的职位，包括在2014年至2017年期间担任首席医疗官，负责疫苗、制药和消费者业务部门的全球患者福祉。他还担任过多个研发领导职务，包括制药业务的首席医疗官、生物制药部门的临床负责人，以及代谢和心血管疾病的治疗领域负责人。在加入葛兰素史克之前，他曾在英国泰恩河畔纽卡斯尔的糖尿病中心担任顾问医生和名誉高级讲师。Stewart博士自2019年3月起担任X4制药董事会成员。他此前曾于2021年7月至2023年5月担任VectivBio Holding AG的董事会成员，并于2023年1月至2023年3月担任阿玛琳 Corporation PLC的董事会成员。Stewart博士拥有南安普顿医学院的医学博士学位，并且是皇家内科医学院的院士。
Murray Stewart,has served as a member of Board since March 2025. Dr. Stewart served as the interim Chief Medical Officer of X4 Pharmaceuticals, Inc., a biopharmaceutical company, from November 2022 to September 2023. He previously served as Senior Medical Advisor of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, from September 2021 to September 2022, and prior to that, as Chief Medical Officer from 2018 to September 2021. He previously served as Head of Research and Development for Novelion Therapeutics Inc., a biopharmaceutical company, from 2017 to 2018. Prior to that, Dr. Stewart held various positions of increasing responsibility at GlaxoSmithKline, including serving as Chief Medical Officer from 2014 to 2017, with global responsibility for patient well-being across the vaccine, pharmaceutical, and consumer business units. He also held multiple research and development leadership roles, including Chief Medical Officer for the pharmaceutical business, Clinical Head of the Biopharma Unit, and Therapy Area Head for metabolic and cardiovascular diseases. Prior to joining GlaxoSmithKline, he worked as a consultant physician and honorary senior lecturer at the Diabetes Center in Newcastle upon Tyne in the United Kingdom. Dr. Stewart has served on the board of directors of X4 Pharmaceuticals since March 2019. He previously served on the boards of directors of VectivBio Holding AG from July 2021 to May 2023, and of Amarin Corporation plc from January 2023 to March 2023. Dr. Stewart holds an DM from Southampton Medical School and is a Fellow of the Royal College of Physicians. - Murray Stewart，自2025年3月起担任董事会成员。Stewart博士于2022年11月至2023年9月期间担任生物制药公司X4 Pharmaceuticals, Inc.的临时首席医疗官。他此前曾于2021年9月至2022年9月担任生物制药公司Rhythm Pharmaceuticals, Inc.的高级医疗顾问，在此之前，于2018年至2021年9月担任首席医疗官。他此前曾于2017年至2018年担任生物制药公司Novelion Therapeutics Inc.的研发主管。在此之前，Stewart博士在葛兰素史克担任过多个职责日益增加的职位，包括在2014年至2017年期间担任首席医疗官，负责疫苗、制药和消费者业务部门的全球患者福祉。他还担任过多个研发领导职务，包括制药业务的首席医疗官、生物制药部门的临床负责人，以及代谢和心血管疾病的治疗领域负责人。在加入葛兰素史克之前，他曾在英国泰恩河畔纽卡斯尔的糖尿病中心担任顾问医生和名誉高级讲师。Stewart博士自2019年3月起担任X4制药董事会成员。他此前曾于2021年7月至2023年5月担任VectivBio Holding AG的董事会成员，并于2023年1月至2023年3月担任阿玛琳 Corporation PLC的董事会成员。Stewart博士拥有南安普顿医学院的医学博士学位，并且是皇家内科医学院的院士。
- Murray Stewart,has served as a member of Board since March 2025. Dr. Stewart served as the interim Chief Medical Officer of X4 Pharmaceuticals, Inc., a biopharmaceutical company, from November 2022 to September 2023. He previously served as Senior Medical Advisor of Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, from September 2021 to September 2022, and prior to that, as Chief Medical Officer from 2018 to September 2021. He previously served as Head of Research and Development for Novelion Therapeutics Inc., a biopharmaceutical company, from 2017 to 2018. Prior to that, Dr. Stewart held various positions of increasing responsibility at GlaxoSmithKline, including serving as Chief Medical Officer from 2014 to 2017, with global responsibility for patient well-being across the vaccine, pharmaceutical, and consumer business units. He also held multiple research and development leadership roles, including Chief Medical Officer for the pharmaceutical business, Clinical Head of the Biopharma Unit, and Therapy Area Head for metabolic and cardiovascular diseases. Prior to joining GlaxoSmithKline, he worked as a consultant physician and honorary senior lecturer at the Diabetes Center in Newcastle upon Tyne in the United Kingdom. Dr. Stewart has served on the board of directors of X4 Pharmaceuticals since March 2019. He previously served on the boards of directors of VectivBio Holding AG from July 2021 to May 2023, and of Amarin Corporation plc from January 2023 to March 2023. Dr. Stewart holds an DM from Southampton Medical School and is a Fellow of the Royal College of Physicians.
- Amir Nashat
-
Amir Nashat, Sc.D.，2008年2月成为Scholar Rock Holding Corporation的董事会成员。自2009年以来，他是Polaris Venture Partners公司（一个风险投资公司）一般合伙人，专注于生命科学投资。他目前是Receptos有限公司董事会和Fate Therapeutics公司董事会成员。他在麻省理工学院的化学工程完成了他的科学博士学位，在Langer博士的指导下辅修生物学。他持有加州大学，伯克利分校材料科学与机械工程硕士和博士学位。
Amir Nashat,has served as a member of Board since 2015. Dr. Nashat is an executive partner at Polaris Partners, a venture capital firm, where he has worked since 2002. Dr. Nashat currently represents Polaris on the board of directors of Morphic Holding, Inc., a biopharmaceutical company developing small molecule integrin therapeutics, where he has served since 2017. Dr. Nashat previously served as a member of the boards of directors of Scholar Rock Holding Corporation from 2012 to June 2024, of Fate Therapeutics, Inc., from 2007 to May 2020, of Selecta Biosciences, Inc., from 2008 to April 2020, and of Syros Pharmaceuticals, Inc., from 2016 to September 2022. Prior to joining Polaris, Dr. Nashat completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology. Dr. Nashat also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley. - Amir Nashat, Sc.D.，2008年2月成为Scholar Rock Holding Corporation的董事会成员。自2009年以来，他是Polaris Venture Partners公司（一个风险投资公司）一般合伙人，专注于生命科学投资。他目前是Receptos有限公司董事会和Fate Therapeutics公司董事会成员。他在麻省理工学院的化学工程完成了他的科学博士学位，在Langer博士的指导下辅修生物学。他持有加州大学，伯克利分校材料科学与机械工程硕士和博士学位。
- Amir Nashat,has served as a member of Board since 2015. Dr. Nashat is an executive partner at Polaris Partners, a venture capital firm, where he has worked since 2002. Dr. Nashat currently represents Polaris on the board of directors of Morphic Holding, Inc., a biopharmaceutical company developing small molecule integrin therapeutics, where he has served since 2017. Dr. Nashat previously served as a member of the boards of directors of Scholar Rock Holding Corporation from 2012 to June 2024, of Fate Therapeutics, Inc., from 2007 to May 2020, of Selecta Biosciences, Inc., from 2008 to April 2020, and of Syros Pharmaceuticals, Inc., from 2016 to September 2022. Prior to joining Polaris, Dr. Nashat completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology. Dr. Nashat also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.
- Andrew J. Schwab
-
Andrew J. Schwab，自2009年起任5：01 Acquisition董事。他是一家生命科学风险投资公司5AM Ventures的创始人兼主理合伙人，且在几家私人生命科学公司的董事会任职。他是一家生命科学风投公司 Bay City Capital的负责人。先前，他曾是Digital Gene Technologies有限公司的业务发展副总裁，以及Montgomery Securities的生命科学投资银行业集团副总裁。他以优异的成绩持有 Davidson College的基因和伦理学学士学位。
Andrew J. Schwab,has served as a member of Board since March 2021. Mr. Schwab is a Founding Partner and Managing Partner of 5AM Venture Management, LLC, a investment firm focused on funding and building next-generation life sciences companies, since 2002. Mr. Schwab has served as a member of the board of directors of Skye Bioscience, Inc., a biopharmaceutical company focused on the development of next-generation treatments for obesity and co-morbidities, since August 2023. Mr. Schwab previously served as a member of the boards of directors of Enliven Therapeutics, Inc., a biopharmaceutical company focused on the development of small molecule kinase inhibitors, from January 2022 to June 2023, of Pear Therapeutics, Inc. from 2014 to June 2022 and of 5:01 Acquisition Corp. from September 2020 to October 2022. Mr. Schwab earned a BS with Honors in Genetics and Ethics from Davidson College. - Andrew J. Schwab，自2009年起任5：01 Acquisition董事。他是一家生命科学风险投资公司5AM Ventures的创始人兼主理合伙人，且在几家私人生命科学公司的董事会任职。他是一家生命科学风投公司 Bay City Capital的负责人。先前，他曾是Digital Gene Technologies有限公司的业务发展副总裁，以及Montgomery Securities的生命科学投资银行业集团副总裁。他以优异的成绩持有 Davidson College的基因和伦理学学士学位。
- Andrew J. Schwab,has served as a member of Board since March 2021. Mr. Schwab is a Founding Partner and Managing Partner of 5AM Venture Management, LLC, a investment firm focused on funding and building next-generation life sciences companies, since 2002. Mr. Schwab has served as a member of the board of directors of Skye Bioscience, Inc., a biopharmaceutical company focused on the development of next-generation treatments for obesity and co-morbidities, since August 2023. Mr. Schwab previously served as a member of the boards of directors of Enliven Therapeutics, Inc., a biopharmaceutical company focused on the development of small molecule kinase inhibitors, from January 2022 to June 2023, of Pear Therapeutics, Inc. from 2014 to June 2022 and of 5:01 Acquisition Corp. from September 2020 to October 2022. Mr. Schwab earned a BS with Honors in Genetics and Ethics from Davidson College.
高管简历
中英对照 | 中文 | 英文- Josh Mandel Brehm
Josh Mandel Brehm，董事Mandel-Brehm先生自2021年9月起担任本公司董事。Mandel-Brehm先生自2017年5月起担任CAMP4 Therapeutics Corporation总裁兼首席执行官，并担任Polaris Partners的企业家合伙人。在2017年5月之前，Mandel-Brehm先生于2013年5月至2017年5月在渤健公司的业务发展部门任职。自2019年10月以来，他还是Vico Therapeutics B.V.的创始人和董事会成员。Mandel-Brehm先生在圣路易斯华盛顿大学获得生物学学士学位，在密歇根大学获得工商管理硕士学位。我们相信Mandel-Brehm先生在生物技术行业的经验使他有资格担任Promis Neurosciences Inc.的董事会成员。
Josh Mandel Brehm,has served as President and Chief Executive Officer of CAMP4 Therapeutics Corporation since May 2017 and as entrepreneur partner with Polaris Partners. Prior to May 2017, Mr. Mandel-Brehm served in business development for Biogen Corporation from May 2013 to May 2017. He has also been a founder and board member for Vico Therapeutics B.V. since October 2019. Mr. Mandel-Brehm earned a Bachelor of Arts degree in Biology from Washington University in St. Louis and a Master of Business Administration from the University of Michigan.- Josh Mandel Brehm，董事Mandel-Brehm先生自2021年9月起担任本公司董事。Mandel-Brehm先生自2017年5月起担任CAMP4 Therapeutics Corporation总裁兼首席执行官，并担任Polaris Partners的企业家合伙人。在2017年5月之前，Mandel-Brehm先生于2013年5月至2017年5月在渤健公司的业务发展部门任职。自2019年10月以来，他还是Vico Therapeutics B.V.的创始人和董事会成员。Mandel-Brehm先生在圣路易斯华盛顿大学获得生物学学士学位，在密歇根大学获得工商管理硕士学位。我们相信Mandel-Brehm先生在生物技术行业的经验使他有资格担任Promis Neurosciences Inc.的董事会成员。
- Josh Mandel Brehm,has served as President and Chief Executive Officer of CAMP4 Therapeutics Corporation since May 2017 and as entrepreneur partner with Polaris Partners. Prior to May 2017, Mr. Mandel-Brehm served in business development for Biogen Corporation from May 2013 to May 2017. He has also been a founder and board member for Vico Therapeutics B.V. since October 2019. Mr. Mandel-Brehm earned a Bachelor of Arts degree in Biology from Washington University in St. Louis and a Master of Business Administration from the University of Michigan.
- David Bumcrot
David Bumcrot，自2020年3月起担任我们的首席科学官和研究高级副总裁。Bumcrot博士此前曾担任我们的副总裁、2017年至2019年3月的生物学负责人以及2019年3月至2020年3月的生物学高级副总裁。在加入CAMP4之前，Bumcrot博士于2014年至2017年在Editas Medicine担任分子与细胞生物学高级总监，在那里他的团队利用突破性的CRISPR技术建立了公司最初的治疗方案。Bumcrot博士此前曾于2012年至2013年担任麻省理工学院科赫综合癌症研究所RNA治疗学实验室的首席研究科学家，并于2002年至2012年在Alnylam Pharmaceutics担任越来越重要的职务，包括最近担任研究主任。Bumcrot博士在康奈尔大学获得生物学学士学位，在宾夕法尼亚大学获得分子生物学博士学位，并在哈佛大学细胞与分子生物学系完成博士后研究。
David Bumcrot,has served as Chief Scientific Officer and Senior Vice President of Research since March 2020. Dr. Bumcrot previously served as Vice President, Head of Biology from 2017 to March 2019 and Senior Vice President of Biology from March 2019 to March 2020. Prior to CAMP4, Dr. Bumcrot served as Senior Director, Molecular & Cell Biology at Editas Medicine from 2014 to 2017, where his team established the company's initial therapeutic programs utilizing groundbreaking CRISPR technology. Dr. Bumcrot previously served as the Head Research Scientist for the Laboratory for RNA Therapeutics at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology from 2012 to 2013, and from 2002 to 2012 served at Alnylam Pharmaceutics in positions of increasing responsibility, including most recently as Director of Research. Dr. Bumcrot earned a BS in Biology from Cornell University, a PhD in Molecular Biology from the University of Pennsylvania and completed a post-doctoral fellowship in the department of Cell & Molecular Biology at Harvard University.- David Bumcrot，自2020年3月起担任我们的首席科学官和研究高级副总裁。Bumcrot博士此前曾担任我们的副总裁、2017年至2019年3月的生物学负责人以及2019年3月至2020年3月的生物学高级副总裁。在加入CAMP4之前，Bumcrot博士于2014年至2017年在Editas Medicine担任分子与细胞生物学高级总监，在那里他的团队利用突破性的CRISPR技术建立了公司最初的治疗方案。Bumcrot博士此前曾于2012年至2013年担任麻省理工学院科赫综合癌症研究所RNA治疗学实验室的首席研究科学家，并于2002年至2012年在Alnylam Pharmaceutics担任越来越重要的职务，包括最近担任研究主任。Bumcrot博士在康奈尔大学获得生物学学士学位，在宾夕法尼亚大学获得分子生物学博士学位，并在哈佛大学细胞与分子生物学系完成博士后研究。
- David Bumcrot,has served as Chief Scientific Officer and Senior Vice President of Research since March 2020. Dr. Bumcrot previously served as Vice President, Head of Biology from 2017 to March 2019 and Senior Vice President of Biology from March 2019 to March 2020. Prior to CAMP4, Dr. Bumcrot served as Senior Director, Molecular & Cell Biology at Editas Medicine from 2014 to 2017, where his team established the company's initial therapeutic programs utilizing groundbreaking CRISPR technology. Dr. Bumcrot previously served as the Head Research Scientist for the Laboratory for RNA Therapeutics at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology from 2012 to 2013, and from 2002 to 2012 served at Alnylam Pharmaceutics in positions of increasing responsibility, including most recently as Director of Research. Dr. Bumcrot earned a BS in Biology from Cornell University, a PhD in Molecular Biology from the University of Pennsylvania and completed a post-doctoral fellowship in the department of Cell & Molecular Biology at Harvard University.
- Kelly Gold
Kelly Gold，自2022年4月起担任我行首席财务官。Gold女士此前曾于2021年4月至2022年3月担任我们的首席商务官，并于2017年至2021年3月在我们公司担任财务和企业发展方面的日益负责的职位。Gold女士此前曾于2014年至2017年在渤健公司担任战略企业融资副总监，在那里她为公司的后期阶段提供财务领导，并营销罕见病项目，并为研发组织制定长期战略财务轨迹。Gold女士此前还曾于2009年至2013年在德意志银行担任医疗保健投资银行助理，曾任职于医疗保健投资银行集团。Gold女士在安大略省皇后大学获得生命科学和机械工程学士学位，并在麻省理工学院斯隆管理学院获得MBA学位。
Kelly Gold,has served as Chief Financial Officer since April 2022. Ms. Gold previously served as Chief Business Officer from April 2021 to March 2022, and held positions of increasing responsibility in Finance and Corporate Development at company from 2017 to March 2021. Ms. Gold previously served as Associate Director, Strategic Corporate Finance at Biogen Inc. from 2014 to 2017, where she provided financial leadership for the company's late stage and marketed rare disease programs and developed long term strategic financial trajectories for the R&D organization. Ms. Gold also previously served as a Healthcare Investment Banking Associate at Deutsche Bank from 2009 to 2013, where she worked in the healthcare investment banking group. Ms. Gold earned bachelor's degrees in Life Sciences and Mechanical Engineering from Queen's University in Ontario and an MBA from the MIT Sloan School of Management.- Kelly Gold，自2022年4月起担任我行首席财务官。Gold女士此前曾于2021年4月至2022年3月担任我们的首席商务官，并于2017年至2021年3月在我们公司担任财务和企业发展方面的日益负责的职位。Gold女士此前曾于2014年至2017年在渤健公司担任战略企业融资副总监，在那里她为公司的后期阶段提供财务领导，并营销罕见病项目，并为研发组织制定长期战略财务轨迹。Gold女士此前还曾于2009年至2013年在德意志银行担任医疗保健投资银行助理，曾任职于医疗保健投资银行集团。Gold女士在安大略省皇后大学获得生命科学和机械工程学士学位，并在麻省理工学院斯隆管理学院获得MBA学位。
- Kelly Gold,has served as Chief Financial Officer since April 2022. Ms. Gold previously served as Chief Business Officer from April 2021 to March 2022, and held positions of increasing responsibility in Finance and Corporate Development at company from 2017 to March 2021. Ms. Gold previously served as Associate Director, Strategic Corporate Finance at Biogen Inc. from 2014 to 2017, where she provided financial leadership for the company's late stage and marketed rare disease programs and developed long term strategic financial trajectories for the R&D organization. Ms. Gold also previously served as a Healthcare Investment Banking Associate at Deutsche Bank from 2009 to 2013, where she worked in the healthcare investment banking group. Ms. Gold earned bachelor's degrees in Life Sciences and Mechanical Engineering from Queen's University in Ontario and an MBA from the MIT Sloan School of Management.
- Yuri Maricich
Yuri Maricich，自2023年8月起担任我们的首席医疗官。Maricich博士目前也是Angelini Ventures的风险投资合伙人和顾问，该公司是一家投资于生物技术、医疗设备和数字健康公司的风险投资公司，自2022年9月以来，他一直在该公司任职。Maricich博士此前曾于2017年至2023年4月担任Pear Therapeutics，Inc.的首席医疗官和开发主管。Pear Therapeutics于2023年4月根据美国破产法第11章申请破产保护。Maricich博士此前曾于2014年至2016年担任Cavion LLC的首席科学官、神经病学副总裁和高级医学总监，并于2011年至2014年担任Xdynia LLC的总裁。他以持牌和董事会认证的内科医生的身份行医，多年来为多家生物技术、医疗设备和数字健康公司以及投资公司提供咨询和咨询，包括在2019年担任罗氏控股公司的科学顾问委员会成员。Maricich博士在圣母大学获得专业前研究学士学位，在华盛顿大学获得医学博士学位，在哈佛大学获得MBA学位。
Yuri Maricich,has served as Chief Medical Officer since August 2023. Dr. Maricich is also currently Venture Partner and Advisor of Angelini Ventures, a venture capital firm investing in biotechnology, medical device, and digital health companies, where he has served since September 2022. Dr. Maricich previously served as Chief Medical Officer and Head of Development of Pear Therapeutics, Inc. from 2017 to April 2023. Pear Therapeutics filed for bankruptcy protection under Chapter 11 of the U.S. Bankruptcy code in April 2023. Dr. Maricich previously served as Chief Scientific Officer as well as VP of Neurology and Senior Medical Director of Cavion LLC from 2014 to 2016 and as President of Xdynia LLC from 2011 to 2014. He has practiced medicine as a licensed and board-certified internal medicine physician and has advised and consulted for a number of biotechnology, pharma, medical device, and digital health companies as well as investment firms over the years, including serving on a Scientific Advisory Board to Roche Holding AG in 2019. Dr. Maricich earned a BS in Pre-Professional Studies from the University of Notre Dame, an MD from the University of Washington, and an MBA from Harvard University.- Yuri Maricich，自2023年8月起担任我们的首席医疗官。Maricich博士目前也是Angelini Ventures的风险投资合伙人和顾问，该公司是一家投资于生物技术、医疗设备和数字健康公司的风险投资公司，自2022年9月以来，他一直在该公司任职。Maricich博士此前曾于2017年至2023年4月担任Pear Therapeutics，Inc.的首席医疗官和开发主管。Pear Therapeutics于2023年4月根据美国破产法第11章申请破产保护。Maricich博士此前曾于2014年至2016年担任Cavion LLC的首席科学官、神经病学副总裁和高级医学总监，并于2011年至2014年担任Xdynia LLC的总裁。他以持牌和董事会认证的内科医生的身份行医，多年来为多家生物技术、医疗设备和数字健康公司以及投资公司提供咨询和咨询，包括在2019年担任罗氏控股公司的科学顾问委员会成员。Maricich博士在圣母大学获得专业前研究学士学位，在华盛顿大学获得医学博士学位，在哈佛大学获得MBA学位。
- Yuri Maricich,has served as Chief Medical Officer since August 2023. Dr. Maricich is also currently Venture Partner and Advisor of Angelini Ventures, a venture capital firm investing in biotechnology, medical device, and digital health companies, where he has served since September 2022. Dr. Maricich previously served as Chief Medical Officer and Head of Development of Pear Therapeutics, Inc. from 2017 to April 2023. Pear Therapeutics filed for bankruptcy protection under Chapter 11 of the U.S. Bankruptcy code in April 2023. Dr. Maricich previously served as Chief Scientific Officer as well as VP of Neurology and Senior Medical Director of Cavion LLC from 2014 to 2016 and as President of Xdynia LLC from 2011 to 2014. He has practiced medicine as a licensed and board-certified internal medicine physician and has advised and consulted for a number of biotechnology, pharma, medical device, and digital health companies as well as investment firms over the years, including serving on a Scientific Advisory Board to Roche Holding AG in 2019. Dr. Maricich earned a BS in Pre-Professional Studies from the University of Notre Dame, an MD from the University of Washington, and an MBA from Harvard University.